Nikkia Diaz
Infectious Disease · Bridgeport, CTNPI 1295173029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Viiv Healthcare Company at 44.5% of the total. 2025 is the largest year on record at $2,455, 7.9 times the $309 reported in 2023.
Across 176 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$806
- AstraZeneca$273
- Pfizer$243
- GSK$199
- Exact Sciences$154
- plus $497 from 8 others
What the payments were for
- Food & beverage$3,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 89 | $1,741 |
| Gilead | 34 | $806 |
| AstraZeneca | 9 | $273 |
| Pfizer | 10 | $243 |
| GSK | 10 | $199 |
| Exact Sciences | 6 | $154 |
| Optinose US, Inc. | 1 | $125 |
| Novo Nordisk | 6 | $112 |
| AbbVie | 3 | $81 |
| Theratechnologies Inc. | 3 | $69 |
| Lilly USA, LLC | 2 | $46 |
| Merck | 1 | $24 |
| Boehringer Ingelheim | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,914 in reported general payments places this provider in the 85th percentile of 159 infectious disease providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 78 | $331,313 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 51 | $210,497 |
| JulucaDolutegravir/Rilpivirine | 25 | $87,846 |
| OzempicSemaglutide | 42 | $49,507 |
| JardianceEmpagliflozin | 28 | $41,679 |
| LinzessLinaclotide | 20 | $19,448 |
| FarxigaDapagliflozin Propanediol | 17 | $18,885 |
| EliquisApixaban | 12 | $16,794 |
| TrulicityDulaglutide | 11 | $10,802 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,084 |
| MenquadfiMening Vac A,c,y,w135,c-Tet/Pf | 18 | $3,096 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $2,387 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,218 |
| Atorvastatin Calcium | 119 | $911 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 14 | $772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $806 | $541,810129 claims |
| Viiv Healthcare CompanyJuluca | $1,741 | $87,84625 claims |
| Novo NordiskOzempic | $112 | $49,50742 claims |
| Boehringer IngelheimJardiance | $20 | $41,67928 claims |
| AbbVieLinzess | $81 | $19,44820 claims |
| AstraZenecaFarxiga | $273 | $18,88517 claims |
| PfizerEliquis | $243 | $16,79412 claims |
| Lilly USA, LLCTrulicity | $46 | $10,80211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 infectious disease providers in Connecticut.
Other infectious disease in Bridgeport
- Kerry WilsonBridgeport$437
- Zane SaulStratford$513K
- Stephen ScholandMeriden$428K
- Onyema OgbuaguNew Haven$412K
- David RubinNorwalk$397K
- Steven SchnittmanWest Haven$363K
- Kalpana GuptaWest Haven$160K
- Frederick AlticeNew Haven$143K
- Paul AnthonyHartford$91K
- Adrian DemidontHamden$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.